A Phase 1, Open-label, study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies after failure of prior standard therapies
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
MEI Pharma, Inc.
Start Date
November 27, 2018
End Date
December 28, 2023
Administered By
Duke Cancer Institute
Awarded By
MEI Pharma, Inc.
Start Date
November 27, 2018
End Date
December 28, 2023